U.S. Direct-to-Consumer Laboratory Testing Market to be Worth $3.91 Billion by 2030

Meticulous Research®, a prominent market research firm, released a report titled, ‘U.S. Direct-to-consumer Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, Thyroid, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood) – Forecast to 2030.’
According to the latest report by Meticulous Research®, the U.S. direct-to-consumer laboratory testing market is forecasted to achieve a value of $3.91 billion by 2030, with a compounded annual growth rate (CAGR) of 10.4% between 2023 and 2030. Several factors are propelling this growth, including the increasing prevalence of chronic diseases and sexually transmitted diseases, higher disposable incomes, heightened consumer awareness, greater emphasis on personal health management, and the advantages of direct-to-consumer (DTC) laboratory testing such as convenience, affordability, and accessibility. Additionally, factors like the rising elderly population, growing interest in ancestry/genealogy testing, and the trend towards predictive testing are contributing to market expansion. Opportunities for further growth include the increasing adoption of telehealth, expansion into emerging markets, and the wider adoption of pharmacogenomic testing within the DTC laboratory testing sector.
Challenges facing the U.S. direct-to-consumer laboratory testing market include concerns regarding genetic data privacy, potential misinterpretation of test results, and the absence of professional medical guidance. Additionally, issues related to sample integrity and interference, regulatory compliance, lack of reimbursement, and a comparatively restricted test selection compared to traditional laboratory testing also impede market growth.
Key Players
The main companies featured in the report on the U.S. direct-to-consumer laboratory testing market include Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), EverlyWell, Inc

U.S. Direct-to-Consumer Laboratory Testing Market to be Worth $3.91 Billion by 2030

Meticulous Research®, a prominent market research firm, released a report titled, ‘U.S. Direct-to-consumer Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, Thyroid, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood) – Forecast to 2030.’
According to the latest report by Meticulous Research®, the U.S. direct-to-consumer laboratory testing market is forecasted to achieve a value of $3.91 billion by 2030, with a compounded annual growth rate (CAGR) of 10.4% between 2023 and 2030. Several factors are propelling this growth, including the increasing prevalence of chronic diseases and sexually transmitted diseases, higher disposable incomes, heightened consumer awareness, greater emphasis on personal health management, and the advantages of direct-to-consumer (DTC) laboratory testing such as convenience, affordability, and accessibility. Additionally, factors like the rising elderly population, growing interest in ancestry/genealogy testing, and the trend towards predictive testing are contributing to market expansion. Opportunities for further growth include the increasing adoption of telehealth, expansion into emerging markets, and the wider adoption of pharmacogenomic testing within the DTC laboratory testing sector.
Challenges facing the U.S. direct-to-consumer laboratory testing market include concerns regarding genetic data privacy, potential misinterpretation of test results, and the absence of professional medical guidance. Additionally, issues related to sample integrity and interference, regulatory compliance, lack of reimbursement, and a comparatively restricted test selection compared to traditional laboratory testing also impede market growth.
Key Players
The main companies featured in the report on the U.S. direct-to-consumer laboratory testing market include Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), EverlyWell, Inc